Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study

Abstract Objective To determine the association between levels of low density lipoprotein cholesterol (LDL-C) and all cause mortality, and the concentration of LDL-C associated with the lowest risk of all cause mortality in the general population. Design Prospective cohort study. Setting Denmark; the Copenhagen General Population Study recruited in 2003-15 with a median follow-up of 9.4 years. Participants Individuals randomly selected from the national Danish Civil Registration System. Main outcome measures Baseline levels of LDL-C associated with risk of mortality were evaluated on a continuous scale (restricted cubic splines) and by a priori defined centile categories with Cox proportional hazards regression models. Main outcome was all cause mortality. Secondary outcomes were cause specific mortality (cardiovascular, cancer, and other mortality). Results Among 108 243 individuals aged 20-100, 11 376 (10.5%) died during the study, at a median age of 81. The association between levels of LDL-C and the risk of all cause mortality was U shaped, with low and high levels associated with an increased risk of all cause mortality. Compared with individuals with concentrations of LDL-C of 3.4-3.9 mmol/L (132-154 mg/dL; 61st-80th centiles), the multivariable adjusted hazard ratio for all cause mortality was 1.25 (95% confidence interval 1.15 to 1.36) for individuals with LDL-C concentrations of less than 1.8 mmol/L (<70 mg/dL; 1st-5th centiles) and 1.15 (1.05 to 1.27) for LDL-C concentrations of more than 4.8 mmol/L (>189 mg/dL; 96th-100th centiles). The concentration of LDL-C associated with the lowest risk of all cause mortality was 3.6 mmol/L (140 mg/dL) in the overall population and in individuals not receiving lipid lowering treatment, compared with 2.3 mmol/L (89 mg/dL) in individuals receiving lipid lowering treatment. Similar results were seen in men and women, across age groups, and for cancer and other mortality, but not for cardiovascular mortality. Any increase in LDL-C levels was associated with an increased risk of myocardial infarction. Conclusions In the general population, low and high levels of LDL-C were associated with an increased risk of all cause mortality, and the lowest risk of all cause mortality was found at an LDL-C concentration of 3.6 mmol/L (140 mg/dL).

[1]  K. Sung,et al.  Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statin Users , 2019, Journal of clinical medicine.

[2]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[3]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[4]  James R. Staley,et al.  Body mass index and all cause mortality in HUNT and UK Biobank studies: linear and non-linear mendelian randomisation analyses , 2019, BMJ.

[5]  A. Khera,et al.  Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease: Results From the Cooper Center Longitudinal Study , 2018, Circulation.

[6]  Sang Min Park,et al.  Association of change in total cholesterol level with mortality: A population-based study , 2018, PloS one.

[7]  Jennifer G. Robinson,et al.  Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis , 2018, JAMA.

[8]  B. Nordestgaard,et al.  Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies , 2017, European heart journal.

[9]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[10]  James R. Staley,et al.  Semiparametric methods for estimation of a nonlinear exposure‐outcome relationship using instrumental variables with application to Mendelian randomization , 2017, bioRxiv.

[11]  B. Nordestgaard,et al.  Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004-2014. , 2017, Atherosclerosis.

[12]  F. Kronenberg,et al.  Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med , 2016, Clinical chemistry.

[13]  S. Thompson,et al.  Instrumental Variable Analysis with a Nonlinear Exposure–Outcome Relationship , 2014, Epidemiology.

[14]  L. Bathum,et al.  Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: A population-based register study , 2013, Scandinavian journal of primary health care.

[15]  B. Nordestgaard,et al.  Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids. , 2012, Danish medical journal.

[16]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[17]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[18]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[19]  K. Christensen,et al.  Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. , 2010, Age and ageing.

[20]  R. Mayeux,et al.  Relation of plasma lipids to all-cause mortality in Caucasian, African-American and Hispanic elders. , 2008, Age and ageing.

[21]  W. Howard Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[22]  J. Greenberg Correcting Biases in Estimates of Mortality Attributable to Obesity , 2006, Obesity.

[23]  J. Staessen,et al.  Low‐Density Lipoprotein Cholesterol and Mortality in Older People , 2005, Journal of the American Geriatrics Society.

[24]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[25]  R. Mayeux,et al.  Relationship Between Plasma Lipids and All‐Cause Mortality in Nondemented Elderly , 2005, Journal of the American Geriatrics Society.

[26]  T. Lumley,et al.  The Association Between Lipid Levels and the Risks of Incident Myocardial Infarction, Stroke, and Total Mortality: The Cardiovascular Health Study , 2004, Journal of the American Geriatrics Society.

[27]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[28]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[29]  M. Trabucchi,et al.  Serum cholesterol levels as a measure of frailty in elderly patients. , 1998, Experimental aging research.

[30]  R A Kronmal,et al.  Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. , 1998, JAMA.

[31]  K C Cain,et al.  Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. , 1993, Archives of internal medicine.

[32]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.